logo
New AI platform helps tribes find funding sources, apply for needed grants, loans

New AI platform helps tribes find funding sources, apply for needed grants, loans

Yahoo18-02-2025

Bazile Panek knows he helped do some good when he sees a tribal representative's sigh of relief after using a new software platform that employs artificial intelligence to find funding opportunities.
'This is going to do great things for Indian Country,' he said.
Panek is the tribal liaison for the company behind the startup AI platform called Syncurrent.
A member of the Red Cliff Band of Lake Superior Ojibwe, Panek saw firsthand the need for services and investment on the reservation in far northern Wisconsin where he was born and raised.
Syncurrent uses AI to quickly gather data from hundreds, even thousands, of websites to find the exact grant, loan or other funding opportunity from federal, state and philanthropic sources that is needed for particular projects and provides information about what's needed to apply.
More artificial intelligence: Want more out of AI? Here are 10 savvy prompts to try out
What used to take hours or days by hand now can take minutes with Syncurrent.
'I hear from so many people who spend more time trying to find grants than actually doing their jobs,' Panek said.
Syncurrent was recently tested by officials for the White Earth Ojibwe Nation in Minnesota.
'The platform's simplicity has allowed us to identify and collaborate on critical funding to meet our community's needs,' said Eugene Sommers, an official for the tribe.
More than a trillion dollars in funding opportunities are available to tribal, local and state governments every year from the federal government, but navigating the process to apply for the funds can be overwhelmingly complex, especially for small staffs.
Syncurrent is the brainchild of technology expert Dhruv Patel and Matthew Jaquez.
The platform's basic plan is free for governments to use; its premium plan is $49 per month per department.
Panek is a longtime colleague of Patel and had urged him to consider the needs of tribal nations early in the development of Syncurrent.
The company recently announced a partnership with the U.S. Department of Interior and the nonprofit Native CDFI Network to make Syncurrent premium free for all tribal nations for 10 years.
'Supporting Tribal Nations is and always will be a main priority for Syncurrent,' said Patel in a statement. 'Through our efforts, we're taking a group of people that have always been pushed to the back of the line and moving them all the way to the front.'
In 2024, Congress approved $32.6 billion in funding to benefit tribal communities, but much of that money may not be reaching them, according to the U.S. Government Accountability Office.
For example, the USDA invested about $6.6 billion to support rural development between 2017 and 2021, but only about $138 million went to tribal communities.
The government department's report blames the red tape and paperwork in finding and applying for funding as a major part of the problem.
'Tribal Nations have long faced systemic barriers to accessing capital and securing their fair share of federal, state, and philanthropic dollars,' said Pete Upton, CEO of Native CDFI Network, in a statement. "Syncurrent's AI technology will enable tribal governments to identify and secure critical funding much more quickly, efficiently, and effectively, empowering them to build stronger, healthier, and more prosperous communities."
Syncurrent can currently be accessed for free by tribal governments through its website, Syncurrent.com.
Frank Vaisvilas is a former Report for America corps member who covers Native American issues in Wisconsin based at the Milwaukee Journal Sentinel. Contact him at fvaisvilas@gannett.com or 815-260-2262. Follow him on Twitter at @vaisvilas_frank.
This article originally appeared on Milwaukee Journal Sentinel: New AI platform helps tribes find funding and apply for federal grants

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025

Business Wire

time9 hours ago

  • Business Wire

Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025

SEATTLE--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced Chief Business Officer Neela Patel, Ph.D., will speak at BIO 2025 on a panel on ' Beyond Bispecifics and ADCs: Conditionally Active Biologics.' Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs. The panel will be held on Wednesday, June 18, 2025, in Room 206AB from 10:15 to 11:15 a.m. ET during the BIO International Convention, which takes place June 16-19, at the Boston International Convention and Exhibition Center. It is open to all registered attendees. Conditionally active biologics (CABs) are an emerging class of drugs that are safer and more efficacious than existing treatments with the potential to overcome the challenges of current state-of-the-art therapies, including ADCs and bispecifics. While companies working in this field are currently focused on oncology and immunology, many of their technologies can be applied to any protein therapeutic where regulation is required to harness a biology for patient benefit. The moderator-led discussion will explore the scientific and commercial landscape for CABs, including types of conditionally active therapeutic modalities currently in research and development, the status of clinical data for these molecules, recent technological advances, and the current and future environment for financings and deals. Patel is a scientist and business development executive with more than 25 years of leadership in drug discovery and development, project and portfolio management, and pipeline development through external innovation. Prior to joining Bonum in 2022, she was part of the executive team at Good Therapeutics, where, as Chief Business Development Officer she co-led the company's acquisition by Roche and the subsequent spinout of Bonum. She will be joined by four panelists representing different perspectives on the technology's potential and challenges, including an investor, an expert in drug development from pharma and scientist executives from biotechnology companies with technologies for regulating biologic therapeutics. Alexandra Cantley, Ph.D., Partner, Polaris Partners Stephen Demerast, Ph.D., Chief Scientific Officer, Tentarix Biotherapeutics Randi Isaacs, MD, Chief Medical Officer, Werewolf Therapeutics John C. Lin, MD, Ph.D., SVP, Immuno-Oncology, Head of Bispecifics R&D, Regeneron Pharmaceuticals Moderator: Michael C. Rice, MS, MBA, SVP, Advanced Therapeutics, Lumanity About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company that uses a novel antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Bonum's most advanced program is in preclinical development. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus milestones. Bonum's unique approach takes advantage of the ability of an antibody to bind specifically and competitively to two distinct antigens – a dual-binding antibody (DBA). The technology brings the power and specificity of an antibody to therapeutic control and is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and Bluesky.

Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025

Yahoo

time9 hours ago

  • Yahoo

Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics SEATTLE, June 10, 2025--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced Chief Business Officer Neela Patel, Ph.D., will speak at BIO 2025 on a panel on "Beyond Bispecifics and ADCs: Conditionally Active Biologics." The panel will be held on Wednesday, June 18, 2025, in Room 206AB from 10:15 to 11:15 a.m. ET during the BIO International Convention, which takes place June 16-19, at the Boston International Convention and Exhibition Center. It is open to all registered attendees. Conditionally active biologics (CABs) are an emerging class of drugs that are safer and more efficacious than existing treatments with the potential to overcome the challenges of current state-of-the-art therapies, including ADCs and bispecifics. While companies working in this field are currently focused on oncology and immunology, many of their technologies can be applied to any protein therapeutic where regulation is required to harness a biology for patient benefit. The moderator-led discussion will explore the scientific and commercial landscape for CABs, including types of conditionally active therapeutic modalities currently in research and development, the status of clinical data for these molecules, recent technological advances, and the current and future environment for financings and deals. Patel is a scientist and business development executive with more than 25 years of leadership in drug discovery and development, project and portfolio management, and pipeline development through external innovation. Prior to joining Bonum in 2022, she was part of the executive team at Good Therapeutics, where, as Chief Business Development Officer she co-led the company's acquisition by Roche and the subsequent spinout of Bonum. She will be joined by four panelists representing different perspectives on the technology's potential and challenges, including an investor, an expert in drug development from pharma and scientist executives from biotechnology companies with technologies for regulating biologic therapeutics. Alexandra Cantley, Ph.D., Partner, Polaris Partners Stephen Demerast, Ph.D., Chief Scientific Officer, Tentarix Biotherapeutics Randi Isaacs, MD, Chief Medical Officer, Werewolf Therapeutics John C. Lin, MD, Ph.D., SVP, Immuno-Oncology, Head of Bispecifics R&D, Regeneron Pharmaceuticals Moderator: Michael C. Rice, MS, MBA, SVP, Advanced Therapeutics, Lumanity About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company that uses a novel antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Bonum's most advanced program is in preclinical development. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus milestones. Bonum's unique approach takes advantage of the ability of an antibody to bind specifically and competitively to two distinct antigens – a dual-binding antibody (DBA). The technology brings the power and specificity of an antibody to therapeutic control and is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and Bluesky. View source version on Contacts Bonum Contact: Neela Patel, Therapeutics(425) 375-5369patel@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Sparkle Inks 25-Unit Deal in Dallas with Franchise Heavyweights
Sparkle Inks 25-Unit Deal in Dallas with Franchise Heavyweights

Yahoo

time03-06-2025

  • Yahoo

Sparkle Inks 25-Unit Deal in Dallas with Franchise Heavyweights

Rapidly-growing pet wellness brand expands its Texas footprint with experienced multi-unit operators at the helm. SCOTTSDALE, Ariz., June 3, 2025 /PRNewswire/ -- Sparkle Grooming Co., the wellness-focused dog grooming franchise redefining pet care, is proud to announce a 25-unit regional development deal in Dallas, Texas, with seasoned franchisees and partners in both life and business, Stacy Hilton + Kumar Patel. The Dallas-based duo brings extensive experience from operating multiple high-performing units of The Joint Chiropractic, where they've earned a reputation for scaling with operational excellence and building strong, people-first teams. Together, Hilton and Patel bring deep expertise across development, training, sales, customer experience, tech-enabled operations, and community engagement, each complementing the other's strengths and sharing a passion for building strong teams and communities. "Sparkle isn't just about dog grooming, it's about joy, trust, and community," said Kumar Patel. "We're thrilled to introduce Sparkle to the Dallas Fort Worth region, where passion meets purpose and every wagging tail tells a story. It's more than a business, it's a movement that gives dogs the best care, pet parents peace of mind, and communities a little more Sparkle!" Their passion for animal wellness runs deep. Both Hilton and Patel have long supported animal rescue initiatives, and see Sparkle as a way to merge their personal values with professional expertise. "Pet parents in Texas deserve an experience that's consistent, compassionate, and truly next-level," said Stacy Hilton. "We're thrilled to bring that to Dallas with Sparkle." With a focus on wellness-first grooming, membership-based care, and local connection, Sparkle offers a modern solution for routine dog care, balancing convenience, consistency, and compassion. Hilton and Patel's first salon is projected to open in early 2026, with plans to quickly scale throughout the greater Dallas metro. This announcement follows a year of hypergrowth for Sparkle, which has now awarded 226 licenses across 12 states, including Arizona, Arkansas, Colorado, Florida, Georgia, Missouri, New Jersey, Ohio, Oklahoma, South Carolina, Texas, and Utah. "Stacy and Kumar are exactly the kind of franchise leaders we look for," said Joe Aeppli, Co-Founder + COO. "They understand what it takes to scale responsibly, build teams that care, and create a loyal community around a brand. We're honored to grow with them." To learn more about franchise opportunities with Sparkle visit: About Sparkle Grooming in 2022, Sparkle Grooming Corp. is on a mission to elevate pet care by blending salon-style grooming with wellness-focused hygiene and neighborhood-level service. Our Quick-Service Pet Care (QSPC) model is designed to keep dogs healthy, happy, and always looking their best while making life easier for busy pet parents. Sparkle's membership-driven approach, compact salon footprint, and operational support systems are helping franchisees nationwide deliver care that's consistent, efficient, and meaningful. Led by a team of industry veterans and brand builders behind globally recognized concepts, Sparkle is redefining what routine pet care looks like in communities across America. View original content to download multimedia: SOURCE Sparkle Grooming Corp. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store